Trump Drug Price Savings Projected to Drop by 80% Due to Pharma Deals
- Projected financial savings from a Trump administration plan to lower Medicare drug costs could plummet by as much as 80%, according to a new analysis examining secret agreements...
Projected financial savings from a Trump administration plan to lower Medicare drug costs could plummet by as much as 80%, according to a new analysis examining secret agreements forged with more than two dozen pharmaceutical companies.
The initiative centers on an approach known as most-favored nation pricing. This policy aims to tie the prices paid by Medicare directly to what 19 other wealthy nations pay for identical medicines. Proponents in the White House have long maintained the effort would slash federal healthcare spending by $26 billion over several years, offering a direct fix for escalating prescription drug costs.
To implement the pricing structure, the administration is establishing two specific pilot programs. The GLOBE program targets Medicare Part B, while the GUARD program focuses on Medicare Part D. Under these frameworks, drug manufacturers face requirements to pay supplementary rebates if their prices rise above the lowest international price found across the designated 19 nations. Specific regulatory details regarding these rules are scheduled for imminent release, according to available reporting.